2026-09-19T08:29:01Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/453532022-01-13T07:54:33Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Darrell J. Irvine.
Song, Andrew, M. Eng. Massachusetts Institute of Technology
Massachusetts Institute of Technology. Dept. of Materials Science and Engineering.
Massachusetts Institute of Technology. Department of Materials Science and Engineering
2009-04-29T17:29:34Z
2009-04-29T17:29:34Z
2008
2008
http://hdl.handle.net/1721.1/45353
316802186
Thesis (M. Eng.)--Massachusetts Institute of Technology, Dept. of Materials Science and Engineering, 2008.
Includes bibliographical references (leaves 66-69).
Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumor cells. Despite the amount of ongoing intensive research to prevent cancer, tumor cells continue to evade immune responses. Currently, dendritic cell vaccines are in development, in which autologous antigen-loaded dendritic cells are injected back into the patient in order to generate an appropriate immune response. Improving upon this idea, members of the Irvine laboratory are in development of an injectable dendritic cell based formulation that gels in situ around the tumor site. In this way, immune cells (most notably T cells) can be recruited and become activated against specific tumor antigens, and (hopefully) kill tumor cells. Recent studies have shown the potential benefit of incorporation of cytokine interleukin-15 complexed with its soluble receptor interleukin-5R[alpha], which is discussed. Economic considerations are also discussed, including topics such as intellectual property, barriers to entry, initial markets and market drivers, and entry into the current supply chain considerations. A business strategy is outlined and evaluated.
by Andrew Song.
M.Eng.
69 leaves
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by
copyright. They may be viewed from this source for any purpose, but
reproduction or distribution in any format is prohibited without written
permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Materials Science and Engineering.
Financial viability and technical evaluation of dendritic cell-carrying "vaccination nodes" for immunotherapy
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="18d83d85-05fe-4529-871d-45afea234e03">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Financial viability and technical evaluation of dendritic cell-carrying "vaccination nodes" for immunotherapy</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2008</PublicationDate>
<Authors>
<Author>
<DisplayName>Song, Andrew, M. Eng. Massachusetts Institute of Technology</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Materials Science and Engineering.</Keyword>
<Abstract>Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumor cells. Despite the amount of ongoing intensive research to prevent cancer, tumor cells continue to evade immune responses. Currently, dendritic cell vaccines are in development, in which autologous antigen-loaded dendritic cells are injected back into the patient in order to generate an appropriate immune response. Improving upon this idea, members of the Irvine laboratory are in development of an injectable dendritic cell based formulation that gels in situ around the tumor site. In this way, immune cells (most notably T cells) can be recruited and become activated against specific tumor antigens, and (hopefully) kill tumor cells. Recent studies have shown the potential benefit of incorporation of cytokine interleukin-15 complexed with its soluble receptor interleukin-5R[alpha], which is discussed. Economic considerations are also discussed, including topics such as intellectual property, barriers to entry, initial markets and market drivers, and entry into the current supply chain considerations. A business strategy is outlined and evaluated.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>